CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
Category: #health  By Mateen Dalal  Date: 2020-02-08
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab

CytoDyn Inc., announced that it has submitted a Phase 2 protocol with the U.S. Food and Drug Administration (FDA) for a basket trial under its cancer IND. The company can instantly start enrollment in this trial to offer therapy for around 22 various solid tumor cancers, such as brain-glioblastoma, melanoma, throat, stomach, lung, colon carcinoma, testicular, breast, ovarian, pancreas, uterine, bladder, among other indications. It is expecting to obtain preliminary outcomes on each subject within 3 to 4 weeks after the initial medication with leronlimab.  CytoDyn will continue to register patients in its metastatic breast cancer studies. 

The basket trial is a Phase 2 study with CCR5+ locally advanced or metastatic solid tumors including 30 subjects. Leronlimab will be administered subcutaneously as a weekly dose of 350 mg. Patients partaking in the trial will be allowed to receive and continue the standard-of-care chemotherapy as defined by the treating physician.

Bruce Patterson, M.D., Founder and Chief Executive Officer, IncellDx, an advisor and a diagnostic partner to CytoDyn, reportedly stated that the outcomes in patients with breast cancer have shown reduction in primary tumors, decrease in CTCs to zero, elimination or shrinking of metastatic lesions and remained stable for several weeks. Other trials demonstrated CTC levels in this cancer >5 and some as high as 20 per 4 mL of blood, he added.

Nader Pourhassan, Ph.D., Chief Executive Officer and President, CytoDyn, reportedly stated that if leronlimab  is able to demonstrate efficacy in this basket trial as the company has observed in the first 4 subjects in its MBC trials, the company will be able to file for another innovative therapy designation (BTD) for the multiple cancer indications evaluated in this study. Since the company started its cancer trials for mTNBC and compassionate usage and extended access for MBC, it has been receiving requests from subjects in the U.S. and overseas, he further added.

Source links:

https://www.cytodyn.com/newsroom/press-releases/detail/382/cytodyn-files-a-phase-2-basket-trial-with-leronlimab-pro

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Lo! Foods bags USD 1 million in pre-series A funding, eyes expansion

Lo! Foods bags USD 1 million in pre-series A funding, eyes expansion

By Mateen Dalal

Lo! Foods, a Bengaluru-based consumer goods startup has reportedly secured USD 1 million during its pre-series A funding round, which was led by Chona Family Office, the former promoters of the renowned Hamvor Ice Cream. Other investors that partici...

U.S. DOJ to intensify review of American Airlines-JetBlue partnership

U.S. DOJ to intensify review of American Airlines-JetBlue partnership

By Mateen Dalal

American Airlines and JetBlue had announced their partnership in July last year. According to the Justice Department, the deal may cause inflated fares at major traffic hubs. The United States Department of Justice (DOJ) has reportedly stepped ...

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

By Mateen Dalal

The two companies intend to introduce their custom-made sub-6GHz 5G chipsets by the end of 2021. UNISOC has managed to raise around USD 817.20 million for its new venture. Chinese electronics giants including Xiaomi Corp. and Guangdong Oppo Mob...